Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0009060 | Colorectum | AD | aerobic respiration | 108/3918 | 189/18723 | 9.14e-28 | 1.43e-24 | 108 |
GO:0045333 | Colorectum | AD | cellular respiration | 119/3918 | 230/18723 | 3.21e-25 | 4.02e-22 | 119 |
GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
GO:0072659 | Colorectum | AD | protein localization to plasma membrane | 122/3918 | 284/18723 | 2.86e-17 | 1.49e-14 | 122 |
GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
GO:1903362 | Colorectum | AD | regulation of cellular protein catabolic process | 109/3918 | 255/18723 | 2.14e-15 | 6.08e-13 | 109 |
GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
GO:1990778 | Colorectum | AD | protein localization to cell periphery | 129/3918 | 333/18723 | 5.51e-14 | 1.15e-11 | 129 |
GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
GO:0032535 | Colorectum | AD | regulation of cellular component size | 142/3918 | 383/18723 | 1.74e-13 | 3.41e-11 | 142 |
GO:1903829 | Colorectum | AD | positive regulation of cellular protein localization | 110/3918 | 276/18723 | 4.58e-13 | 8.44e-11 | 110 |
GO:0006839 | Colorectum | AD | mitochondrial transport | 102/3918 | 254/18723 | 1.87e-12 | 3.08e-10 | 102 |
GO:1903050 | Colorectum | AD | regulation of proteolysis involved in cellular protein catabolic process | 92/3918 | 221/18723 | 2.04e-12 | 3.19e-10 | 92 |
GO:0031330 | Colorectum | AD | negative regulation of cellular catabolic process | 104/3918 | 262/18723 | 2.66e-12 | 3.96e-10 | 104 |
GO:0072594 | Colorectum | AD | establishment of protein localization to organelle | 148/3918 | 422/18723 | 7.95e-12 | 1.04e-09 | 148 |
GO:0002064 | Colorectum | AD | epithelial cell development | 89/3918 | 220/18723 | 2.98e-11 | 3.52e-09 | 89 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa05017 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05213 | Colorectum | AD | Endometrial cancer | 29/2092 | 58/8465 | 2.69e-05 | 2.57e-04 | 1.64e-04 | 29 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa05418 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
hsa04152 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
hsa05210 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
hsa04213 | Colorectum | AD | Longevity regulating pathway - multiple species | 27/2092 | 62/8465 | 8.72e-04 | 5.96e-03 | 3.80e-03 | 27 |
hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AKT1 | SNV | Missense_Mutation | novel | c.618N>T | p.Arg206Ser | p.R206S | P31749 | protein_coding | tolerated(0.32) | benign(0.023) | TCGA-A7-A13G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | PD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AKT1 | SNV | Missense_Mutation | | c.155N>G | p.Leu52Arg | p.L52R | P31749 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AN-A0XR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A12H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49N>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49N>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0BS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49N>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | inhibitor | CHEMBL3545422 | MIRANSERTIB | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | inhibitor | CHEMBL3545134 | LY-2780301 | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | inhibitor | PERIFOSINE | PERIFOSINE | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | inhibitor | 385612197 | | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TRICIRIBINE | TRICIRIBINE | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | Cetuximab | CETUXIMAB | 25714871 |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | inhibitor | CHEMBL3545000 | MK-2201 | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | allosteric modulator | 405560349 | | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | AKT INHIBITOR VIII | CHEMBL258844 | 17603540 |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CI-1033 | CANERTINIB | |